GNI Group FY2024 revenue down 9.2%, operating profit plunges 89.3%; Gyre pipeline catalysts set for 2025

GYRE THERAPEUTICS, INC.

2024-FY EPS reported $0.05 revenue$105,757,000

Revenue ¥23,611M (-9.2% YoY); operating profit ¥1,402M (-89.3%); pre-tax profit ¥238M (-98.1%).
Net loss attributable to owners of parent ¥977M (vs. ¥8,094M profit in FY2023); basic EPS ¥19.55 (vs. ¥169.50).
Operating cash flow negative ¥3,164M; investing cash outflow ¥10,361M; cash position ¥10,115M.
Gyre Pharms: Hydronidone Phase 3 topline data expected Q1 2025; F573 Ph2 completion, F230 Ph1 start planned.
F528 IND submission targeted for Dec 2025; GNI Group forecasts FY2025 revenue ¥28,733M (+21.7% YoY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.